INTRODUCTION
============

Ischemic complications after immediate breast reconstruction, whether implant- or autologous-based, carry significant clinical consequences including reconstructive failure.^[@R1]--[@R4]^ Rates of mastectomy flap necrosis after immediate reconstruction continue to be established but range from 3% to 40% depending on the severity.^[@R1]^ A myriad of patient-, operative-, and surgeon-specific factors influences the risk of ischemic complications.^[@R4],[@R5]^ However, predicting individual patient risk remains challenging.

Various technological devices have been employed to assist in prediction of postoperative ischemic complications.^[@R6]--[@R9]^ Such modalities largely include tissue angiography and spectroscopy.^[@R6]--[@R9]^ Although these technologies have demonstrated variable effectiveness in reducing the incidence of postoperative ischemic complications in immediate breast reconstruction, they introduce a large cost burden that limits their implementation.^[@R6],[@R7]^ Therefore, we sought to develop an intraoperative mastectomy flap risk assessment tool to assist in both estimating risk of ischemic complications and aid in clinical decision-making to optimize outcomes in immediate breast reconstruction.

METHODS
=======

Patients undergoing immediate implant- or autologous-based breast reconstruction at a major metropolitan public medical center without availability of fluorescent angiography were prospectively identified. Patient demographics, comorbidities, and oncologic characteristics were recorded. Three breast surgeons and 5 plastic surgeons were involved in the care of these patients.

Intraoperatively, each reconstruction was evaluated with an intraoperative mastectomy flap ischemia risk assessment tool by an independent surgeon. The risk assessment tool consisted of 8 binary questions, as determined by the authors, to be answered by the independent surgeon that covered clinical assessments of flap perfusion and flap thickness, and use of methylene blue, electrocautery and infiltration of a 0.5% lidocaine, 1:200,000 epinephrine solution (Fig. [1](#F1){ref-type="fig"}). Higher scores were hypothesized to correlate with greater risk of ischemic complications. Location of any intraoperative mastectomy flap compromise and general breast measurements were also recorded. Mastectomy flap tissue was not routinely trimmed during the operation. Patients were then prospectively evaluated postoperatively for the occurrence of any ischemic complications at each postoperative follow-up office visit. Ischemic complications were defined as any impending or actual tissue/skin loss of the mastectomy flaps. Partial-thickness necrosis was defined as that managed with local wound care. Full-thickness necrosis was defined as that managed with debridement in either the office or the operating room. Locations of postoperative ischemic complications were also noted (**see document, Supplemental Digital Content 1**, which displays the worksheets for intra- and postoperative mastectomy flap evaluation, **<http://links.lww.com/PRSGO/B273>**).

![Clinical intraoperative mastectomy flap risk assessment tool.](gox-7-e2585-g001){#F1}

Descriptive statistics and measure of central tendency were used to describe absolute and mean results, respectively. Student's *t* tests were used to analyze continuous data sets, whereas chi-square tests were used to compare proportional responses. Univariate analysis was performed to evaluate for independent risk factors for the occurrence of ischemic complications. The risk for occurrence of an ischemic complication for each total score of the risk assessment tool was calculated. A correlation value was also determined for the correlation between risk assessment score and rate of ischemic complications. Sensitivity, specificity, and positive and negative predictive values were calculated for correlation between the presence of intraoperative mastectomy flap compromise and postoperative mastectomy flap ischemic complications. A subgroup analysis was also performed comparing risk assessment scores and rate of ischemic complications between implant-based and autologous-based reconstructions.

Statistical analysis was performed using GraphPad Software, Inc. (La Jolla, CA). A *P* value of less than 0.05 was considered significant.

RESULTS
=======

Thirty-one patients underwent 45 immediate breast reconstructions after mastectomy. Average age and body mass index were 47.71 years and 27.77 kg/m^2^. Two (4.4%) and 3 (6.7%) patients, respectively, were active and former tobacco smokers. The rates of prior radiation and chemotherapy were 13.3% and 40.0%, respectively. Rates of adjuvant radiation and chemotherapy were 15.6% and 13.3%. The majority of mastectomies were skin sparing (93.3%) and for therapeutic indications (62.2%). Of all cases, 57.8% underwent concurrent sentinel lymph node biopsy or axillary lymph node dissection. The most common clinical breast cancer stages were stage 0 (46.7%), IA (24.4%), and IIA (11.1%). The majority of reconstructions were tissue expander based (64.4%) followed by autologous based (35.6%). The majority (69.0%) of tissue expander-based reconstructions utilized acellular dermal matrices. Average breast measurements were 22.93 cm for sternal notch to nipple, 9.36 cm for nipple to inframammary fold, 14.09 cm for breast width, 15.04 cm for incision to clavicle, and 6.39 cm for incision to inframammary fold. Average follow-up was 11.16 months (Table [1](#T1){ref-type="table"}).

###### 

Overall Demographics and Surgical Characteristics of Patients Undergoing Immediate Breast Reconstruction after Mastectomy Assessed with the Mastectomy Flap Ischemia Risk Score

  -----------------------------------------------------------------------------------------------
  No. (Patients)                              31
  ------------------------------------------- ---------------------------------------------------
  No. (breasts)                               45

  Age, y                                      47.71

  Body mass index, kg/m~2~                    27.77

  Mastectomy indication                       Therapeutic: 28 (62.2%); prophylactic: 17 (37.8%)

  Smoking history                             Active: 2 (4.4%); former: 3 (6.7%)

  Prior radiation                             6 (13.3%)

  Prior chemotherapy                          18 (40.0%)

  Lymph node biopsy or dissection performed   26 (57.8%)

  Adjuvant radiation                          7 (15.6%)

  Adjuvant chemotherapy                       6 (13.3%)

  Pathologic breast cancer stage              0: 21 (46.7%)

                                              IA: 11 (24.4%)

                                              IB: 2 (4.4%)

                                              IIA: 5 (11.1%)

                                              IIB: 3 (6.7%)

                                              IIIA: 2 (4.4%)

                                              IIIC: 1 (2.2%)

  Mastectomy type                             Skin-sparing mastectomy: 42 (93.3%)\
                                              Nipple-sparing mastectomy: 3 (6.7%)

  Mastectomy incision                         Ellipse: 42 (93.3%)\
                                              Inframammary fold: 3 (6.7%)

  Sternal notch--nipple distance, cm          22.93 (36)

  Nipple--inframammary fold distance, cm      9.36 (36)

  Breast width, cm                            14.09 (41)

  Incision--clavicle distance, cm             15.04 (43)

  Incision--inframammary fold distance, cm    6.39 (43)

  Reconstructive modality                     Tissue expander: 29 (64.4%)\
                                              Autologous: 16 (35.6%)

  Acellular dermal matrix                     20 (69.0%)

  Follow-up, mo                               11.16
  -----------------------------------------------------------------------------------------------

Overall, 16 reconstructions (35.6%) experienced an ischemic complication with 7 (15.6%) and 9 (20.0%) incidences of full- and partial-thickness mastectomy flap necrosis, respectively. There were 2 incidences (4.4%) of reconstructive failure related to an ischemic complication. Nonischemic complications included minor cellulitis (2.2%) and hematoma (6.7%) (Table [2](#T2){ref-type="table"}).

###### 

Overall Reconstructive Complications in Patients Undergoing Immediate Breast Reconstructions after Mastectomy Assessed with the Mastectomy Flap Ischemia Risk Score

  Ischemic Complications                                    
  --------------------------------------------------------- -----------
  Full-thickness mastectomy flap necrosis                   7 (15.6%)
  Partial-thickness mastectomy flap necrosis                9 (20.0%)
  Explantation (related to mastectomy flap necrosis)        2 (4.4%)
  Nonischemic complications                                 
   Cellulitis (oral antibiotics)                            1 (2.2%)
   Explantation (not related to mastectomy flap necrosis)   3 (6.7%)
   Breast hematoma                                          3 (6.7%)
   Abdominal wound breakdown                                2 (4.4%)
   Pulmonary embolus                                        2 (4.4%)

In univariate analysis, the only factor found to be independently predictive of ischemic complications was having a sentinel lymph node biopsy performed (*P* = 0.0453). No other factors, including elevated body mass index (*P* = 0.1377), prior radiation (*P* = 0.4332) or chemotherapy (*P* = 0.7994), sternal notch--nipple distance ≥25 cm (*P* = 0.2689), or nipple--inframammary fold distance ≥10 cm (*P* = 0.8639), among others, were significantly predictive for the occurrence of an ischemic complication (Table [3](#T3){ref-type="table"}).

###### 

Univariate Analysis of Risk Factors for Ischemic Complications after Mastectomy with Immediate Breast Reconstruction Including the Mastectomy Flap Ischemia Risk Score

  Variable                                    Total Mastectomies (N)   Mastectomies with Ischemic Complication (%)   Unadjusted OR (95% CI)     *P*
  ------------------------------------------- ------------------------ --------------------------------------------- -------------------------- ------------
  No.                                         45                                                                     --                         --
  Age                                                                                                                                           
   \<50 y                                     24                       7 (29.2%)                                     1.8214 (0.5305--6.2540)    0.3407
   ≥50 y                                      21                       9 (42.9%)                                                                
  BMI                                                                                                                                           
   \<30 kg/m^2^                               29                       8 (27.6%)                                     2.6250 (0.7341--9.3864)    0.1377
   ≥30 kg/m^2^                                16                       8 (50.0%)                                                                
  Current smoking                                                                                                                               
   Yes                                        2                        1 (50.0%)                                     1.8667 (0.1089--32.0108)   0.6669
   No                                         43                       15 (34.9%)                                                               
  Therapeutic indication                                                                                                                        
   Yes                                        28                       12 (42.9%)                                    2.4375 (0.6334--9.3803)    0.1950
   No                                         17                       4 (23.5%)                                                                
  Sentinel lymph node biopsy performed                                                                                                          
   Yes                                        19                       10 (52.6%)                                    3.7037 (1.0278--13.3467)   **0.0453**
   No                                         26                       6 (23.1%)                                                                
  Axillary lymph node dissection performed                                                                                                      
   Yes                                        7                        1 (14.3%)                                     0.2556 (0.0279--2.3406)    0.2273
   No                                         38                       15 (39.5%)                                                               
  Prior radiation                                                                                                                               
   Yes                                        6                        3 (50.0%)                                     2.0000 (0.3534--11.3186)   0.4332
   No                                         39                       13 (33.3%)                                                               
  Prior chemotherapy                                                                                                                            
   Yes                                        18                       6 (33.3%)                                     0.8500 (0.2427--2.9763)    0.7994
   No                                         27                       10 (37.0%)                                                               
  Adjuvant radiation                                                                                                                            
   Yes                                        7                        2 (28.6%)                                     0.6857 (0.1171--4.0151)    0.6756
   No                                         38                       14 (36.8%)                                                               
  Adjuvant chemotherapy                                                                                                                         
   Yes                                        6                        0 (0.0%)                                      0.1096 (0.0058--2.0819)    0.1410
   No                                         39                       16 (41.0%)                                                               
  Nipple-sparing mastectomy                                                                                                                     
   Yes                                        3                        0 (0.0%)                                      0.2294 (0.0111--4.7313)    0.3404
   No                                         42                       16 (38.1%)                                                               
  Implant-based reconstruction                                                                                                                  
   Yes                                        29                       11 (37.9%)                                    1.3444 (0.3678--4.9146)    0.6545
   No                                         16                       5 (31.3%)                                                                
  Acellular dermal matrix                                                                                                                       
   Yes                                        20                       7 (35.0%)                                     0.6731 (0.1353--3.3474)    0.6286
   No                                         9                        4 (44.4%)                                                                
  Sternal notch--nipple distance ≥25 cm                                                                                                         
   Yes                                        13                       7 (53.8%)                                     2.1875 (0.5462--8.7612)    0.2689
   No                                         23                       8 (34.8%)                                                                
  Nipple--inframammary fold distance ≥10 cm                                                                                                     
   Yes                                        15                       6 (40.0%)                                     0.8889 (0.2312--3.4181)    0.8639
   No                                         21                       9 (42.9%)                                                                
  Mastectomy flap ischemia risk score \>5                                                                                                       
   Yes                                        9                        5 (55.6%)                                     2.8409 (0.6378--12.6541)   0.1707
   No                                         36                       11 (30.6%)                                                               
  Mastectomy flap ischemia risk score \>6                                                                                                       
   Yes                                        6                        4 (66.7%)                                     4.5000 (0.7229--28.0120)   0.1069
   No                                         39                       12 (30.8%)                                                               
  Mastectomy flap ischemia risk score \>7                                                                                                       
   Yes                                        4                        3 (75.0%)                                     6.4615 (0.6120--68.2200)   0.1207
   No                                         41                       13 (31.7%)                                                               

Bold text indicates a significant *P* value.

BMI, body mass index.

The average total mastectomy flap ischemic risk score was 4.29 out of a maximum score of 8. The highest average item score was for utilizing cautery to perform the mastectomy (average score: 1.00), whereas the lowest average item score was for the presence of skin edge bleeding (average score: 0.27). The highest rates of ischemic complications were observed in reconstructions with total mastectomy flap ischemia risk scores of 5 (35.7%), 2 (42.9%), 7 (50.0%), and 8 (75.0%). The correlation value of higher mastectomy flap ischemia risk scores with increasing incidence of ischemic complications was 0.65 (Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}) (Fig. [2](#F2){ref-type="fig"}). The location of intraoperative mastectomy flap compromise correlated with the location of postoperative mastectomy flap ischemia in 75% of reconstructions with ischemic complications.

###### 

Average Overall Scoring Calculated with the Mastectomy Flap Ischemia Risk Score

  No.        Risk Factor                                                                                Average Score (Range 0.00--1.00)
  ---------- ------------------------------------------------------------------------------------------ ----------------------------------
  1          Flap visibly mottled (0: no, 1: yes)                                                       0.29
  2          Dermis visible (0: no, 1: yes)                                                             0.62
  3          Capillary refill present (1: no, 0: yes)                                                   0.29
  4          Cautery utilized for mastectomy (0: no, 1: yes)                                            1.00
  5          Methylene blue injected into dermis (0: no, 1: yes)                                        0.42
  6          Skin edge bleeding present (1: no, 0: yes)                                                 0.27
  7          Pinch test \<1 cm (0: no, 1: yes)                                                          0.71
  8          0.5% lidocaine 1:200,000 epinephrine solution injected before mastectomy (0: no, 1: yes)   0.69
  Sum 1--8   Overall score                                                                              4.29

###### 

Ischemic Complications Stratified by Overall Mastectomy Flap Ischemia Risk Score

  -----------------------------------------------------------------------------------------------------
  Overall Score   N    Ischemic Complications                                   Correlating Locations
  --------------- ---- -------------------------------------------------------- -----------------------
   0              0    N/A                                                      N/A

   1              3    Overall: 1 (33.3%)\                                      0 (0.0%)
                        Full-thickness mastectomy flap necrosis: 0 (0.0%)\      
                        Partial-thickness mastectomy flap necrosis: 1 (33.3%)   

   2              7    Overall: 3 (42.9%)\                                      1 (33.3%)
                        Full-thickness mastectomy flap necrosis: 0 (0.0%)\      
                        Partial-thickness mastectomy flap necrosis: 3 (42.9%)   

   3              6    Overall: 2 (33.3%)\                                      1 (50.0%)
                        Full-thickness mastectomy flap necrosis: 1 (16.7%)\     
                        Partial-thickness mastectomy flap necrosis: 1 (16.7%)   

   4              6    Overall: 0 (0.0%)\                                       N/A
                        Full-thickness mastectomy flap necrosis: 0 (0.0%)\      
                        Partial-thickness mastectomy flap necrosis: 0 (0.0%)    

   5              14   Overall: 5 (35.7%)\                                      5 (100.0%)
                        Full-thickness mastectomy flap necrosis: 2 (14.3%)\     
                        Partial-thickness mastectomy flap necrosis: 3 (21.4%)   

   6              3    Overall: 1 (33.3%)\                                      1 (100.0%)
                        Full-thickness mastectomy flap necrosis: 1 (33.3%)\     
                        Partial-thickness mastectomy flap necrosis: 0 (0.0%)    

   7              2    Overall: 1 (50.0%)\                                      1 (100.0%)
                        Full-thickness mastectomy flap necrosis: 1 (50.0%)\     
                        Partial-thickness mastectomy flap necrosis: 0 (0.0%)    

   8              4    Overall: 3 (75.0%)\                                      3 (100.0%)
                        Full-thickness mastectomy flap necrosis: 2 (50.0%)\     
                        Partial-thickness mastectomy flap necrosis: 1 (25.0%)   
  -----------------------------------------------------------------------------------------------------

N/A, not applicable.

![Overall ischemic complications stratified by mastectomy flap ischemia risk score.](gox-7-e2585-g002){#F2}

Reconstructions with a total mastectomy flap ischemia risk score of greater than 5 had a significantly higher rate of ischemic complications compared to reconstructions with a score of 5 or less (*P* = 0.0025). Similarly, reconstructions with a score of \>6 and \>7 had significantly higher rates of ischemic complications (*P* \< 0.0001, each) compared to reconstructions with scores of ≤6 and ≤7, respectively (Table [6](#T6){ref-type="table"}). Total mastectomy flap ischemia risk scores of \>5 \[odds ratio (OR) = 2.8409; *P* = 0.1707\], \>6 (OR = 4. 500; *P* = 0.1069), and \>7 (OR = 6.4615; *P* = 0.1207) all trended toward significance on univariate analysis.

###### 

Comparison of Ischemic Complications by Mastectomy Flap Ischemia Risk Score Thresholds

  Mastectomy Flap Ischemia Score (X)   Score ≤X        Score \>X       *P*
  ------------------------------------ --------------- --------------- --------------
  0                                    0/0 (N/A)       16/45 (35.6%)   --
  1                                    1/3 (33.3%)     15/42 (35.7%)   0.9318
  2                                    4/10 (40.0%)    12/35 (34.3%)   0.7042
  3                                    6/16 (37.5%)    10/29 (34.5%)   0.8007
  4                                    6/22 (27.3%)    10/23 (43.5%)   0.1247
  5                                    11/36 (30.6%)   5/9 (55.6%)     **0.0025**
  6                                    12/39 (30.8%)   4/6 (66.7%)     **\<0.0001**
  7                                    13/41 (31.7%)   3/4 (75.0%)     **\<0.0001**
  8                                    16/45 (35.6%)   0/0 (N/A)       --

Bold text indicates a significant *P* value.

N/A, not applicable.

The correlation between presence of intraoperative mastectomy flap compromise and postoperative mastectomy flap ischemic complications was then assessed. The sensitivity and specificity of intraoperative mastectomy flap compromise were 81.25% and 62.07%. The positive and negative predictive values were 54.17% and 85.71% (Table [7](#T7){ref-type="table"} and [8](#T8){ref-type="table"}).

###### 

Correlation between Intraoperative Mastectomy Flap Compromise and Postoperative Mastectomy Flap Ischemic Complications

                                                  Area of Postoperative Ischemic Complications (N = 16)   No Area of Postoperative Ischemic Complications (N = 29)   
  ----------------------------------------------- ------------------------------------------------------- ---------------------------------------------------------- ----
  Area of intraoperative compromise (N = 24)      13                                                      11                                                         24
  No Area of intraoperative compromise (N = 21)   3                                                       18                                                         21
                                                  16                                                      29                                                         

Sensitivity = 81.25% (95% CI: 54.35%--95.95%); specificity = 62.07% (95% CI: 42.26%--79.31%); positive predictive value = 54.17% (95% CI: 41.23%--66.57%); negative predictive value = 85.71% (95% CI: 67.54%--94.54%).

CI, confidence interval.

###### 

Subgroup Analysis Comparing Outcomes in Implant-based and Autologous Reconstructions

                           Implant-based Reconstruction (N = 29)   Autologous Reconstruction (N = 16)   *P*
  ------------------------ --------------------------------------- ------------------------------------ --------
  Average score            4.14                                    4.56                                 0.4881
  Ischemic complications   11 (37.9%)                              5 (31.3%)                            0.5835

Lastly, a subgroup analysis was performed comparing risk assessment scores and rate of ischemic complications between implant-based and autologous-based reconstructions (Table [8](#T8){ref-type="table"}). The average risk assessment scores for implant and autologous reconstructions were 4.14 and 4.56, respectively (*P* = 0.4881). Similarly, rates of ischemic complications between the groups were statistically comparable (37.9% versus 31.3%; *P* = 0.5835).

DISCUSSION
==========

As extirpative breast techniques have evolved from the radical mastectomy of Halsted to nipple-sparing mastectomy, an emphasis has been placed on increasing preservation of the breast skin envelope with conserved oncologic safety.^[@R10]--[@R14]^ Such technical advances have enhanced aesthetic and reconstructive outcomes while also demonstrating improved patient-reported outcomes.^[@R15],[@R16]^ However, increasing skin preservation places increased stress on the tissue itself given its relative hypovascular status after mastectomy.^[@R1]^ Post mastectomy, breast skin flap perfusion is largely based on the contribution of the superficial vasculature in the subdermal and subcutaneous tissues.^[@R17]--[@R21]^ When damage is incurred by this superficial vasculature, breast flap ischemia will ensue in the form of mastectomy flap necrosis, which may include the nipple-areola complex in nipple-sparing mastectomy.^[@R17]^

Ischemic complications after immediate breast reconstruction can have devastating consequences. Full-thickness mastectomy flap necrosis in implant-based reconstruction risks device exposure and reconstructive failure. In autologous breast reconstruction, full-thickness skin flap necrosis predisposes to poor wound healing, potential need for skin grafting, and ultimate compromise of final aesthetic result. In both reconstructive modalities, partial-thickness mastectomy flap necrosis will likewise impede wound healing, result in increased scarring, and potentially progress to full-thickness necrosis and reconstructive failure.^[@R17],[@R22]^

A myriad of patient-, operative-, and surgeon-specific factors has been identified as risk factors for ischemic complications.^[@R4],[@R5]^ These include prior surgery, mastectomy type, indication and incision, dissection technique, body mass index, breast size, and diabetes, among others.^[@R4],[@R5],[@R23],[@R24]^ Perhaps the most important factor in minimizing risk of ischemic complications in immediate breast reconstruction is the quality of the postmastectomy breast skin envelope.^[@R17],[@R25],[@R26]^ Mastectomy flap quality can be optimized by performing dissection at the level of the breast capsule, preserving subcutaneous tissue to maximize oncologic resection and minimize damage to the superficial vascular plexus supplying the skin flaps.^[@R25],[@R26]^ Despite these considerations, estimating individual patient risk for ischemic complications after immediate breast reconstruction remains challenging.

Clinical examination of skin flap variability remains the gold standard of evaluation.^[@R1]^ However, clinical evaluation is limited by subtle changes in examination belying subclinical ischemia and limited ability for assessment of capillary refill in darker skin tones.^[@R1]^ Given the significant repercussions of poor skin flap perfusion, multiple adjunctive technological modalities to assess perfusion have been developed.^[@R6]--[@R9],[@R27]--[@R30]^ These largely include various forms of tissue angiography and spectroscopy to provide additional information regarding impaired tissue perfusion to guide the surgeon in minimizing risk for postoperative mastectomy flap ischemia.^[@R6]--[@R9],[@R27]--[@R30]^ Any decreased flow may lead the surgeon to remove devascularized tissue, decrease intraoperative tissue expander fill, change the operative plan from immediate permanent implant to tissue expander placement, or bank flap skin in autologous reconstruction, among other maneuvers to mitigate tissue loss.^[@R25]--[@R31]^ These technologies, however, add significant cost to the operation, which limits their implementation in all clinical scenarios and hospital systems. We therefore sought to develop a simple, easy-to-implement risk assessment tool to assist surgeons in predicting risk for mastectomy flap ischemic in immediate breast reconstruction.

The risk assessment tool consisted of 8 binary questions that the operating surgeon answered intraoperatively. Higher scores indicated a greater perceived risk of mastectomy flap compromise. Any areas of compromise were also localized on the mastectomy skin flaps. To assess this risk assessment tool, 45 immediate breast reconstructions were prospectively identified and evaluated at a large, public, and metropolitan medical center without access to adjunctive skin perfusion assessment technologies. The majority of reconstructions were tissue expander based after therapeutic skin-sparing mastectomy with an average follow-up of nearly 12 months. The overall rate of ischemic complications, being partial- or full-thickness mastectomy flap or nipple-areola complex necrosis, was 35.6%. Importantly, the rate of reconstructive failure secondary to ischemic complications was 4.4%.

On univariate analysis of individual risk factors analyzed in this cohort, the only variable significantly associated with ischemic complications was the performance of a sentinel lymph node biopsy (*P* = 0.0453). This may be explained as a sentinel lymph node biopsy will inherently involve increased dissection during mastectomy, especially if performed through the mastectomy incision rather than a separate axillary incision. This increased dissection may result in increased retraction on the skin flaps or inadvertent iatrogenic injury to the skin flaps during biopsy, leading to mastectomy flap compromise. Notably, in both univariate analysis and subgroup analysis, outcomes and risk scores in implant- or autologous-based reconstruction were equivalent.

The average risk assessment score for all reconstructions was 4.29/8. A positive correlation between higher scores and greater incidence of ischemic complications was established, confirming the designed objective of the tool. Importantly, risk assessment scores greater than 5, greater than 6, and greater than 7 all were significantly associated with higher rates of ischemic complications. Likewise, scores greater than these values all trended toward significance on univariate analysis. These findings indicate that a score of 6 or higher represents a threshold value above which a reconstruction may be expected to have a significantly higher risk of ischemic complications. Scores of 6 or higher therefore should encourage the surgeon to mitigate risk of ischemic complications by excising compromised tissue or decreasing stress on the mastectomy flaps.

Upon further evaluation of this risk assessment tool, the sensitivity and specificity of intraoperative mastectomy flap compromise based on the tool and postoperative ischemia were 81.25% and 62.07%. Positive and negative predictive values were 54.17% and 85.71%. These findings indicate that this risk assessment tool is effective at ruling out mastectomy flap ischemia and less effective in ruling in ischemic events. Thus, a low score and lack of clinical mastectomy flap compromise should reassure the surgeon that there is low risk for postoperative ischemia. These characteristics are advantageous in such a tool as the risk of a false-negative result, being unexpected postoperative ischemia, is much greater than a false-positive result, being lack of postoperative ischemia in the face of predicted intraoperative compromise.

Overall, we have developed a simple tool to assess risk for mastectomy flap ischemia after immediate breast reconstruction while demonstrating its effectiveness in accomplishing its aim. A threshold value of 6 was also established, above which the surgeon is recommended to take action in mitigating risk of postoperative ischemia and potential reconstructive compromise. While exhibiting worthy specificity, this tool displays particular sensitivity and efficacy in ruling out postoperative ischemia in the absence of intraoperative mastectomy flap compromise. This tool supplements basic clinical judgment by providing the surgeon with objective and binary points to measure in determining a final score. Further, our tool is not reliant on any adjunctive perfusion assessment technologies, which may be cost-prohibitive in certain circumstances such as the public medical center in which this study was performed. Although individual factors in the tool were not examined but rather assessed as a whole to increase reliability, each individual factor can be addressed in a manner to increase chances of a successful reconstruction. For example, the need for methylene blue dye or its judicious application should be discussed with the ablative surgeon. Similarly, use of electrocautery should be minimized. This tool may encourage and facilitate these collaborative approaches between the extirpative and reconstructive breast teams to optimize outcomes. Prior studies have retrospectively developed a scoring system to assess mastectomy flap necrosis.^[@R32]^ However, ours is the first to prospectively evaluate a clinical, intraoperative tool to assess mastectomy flap ischemia.

Limitations of this study include its reliance on surgeon reporting of postoperative complications including the degree of postoperative mastectomy ischemia, if present. However, the prospective nature of this study ensures that patient identification and data collection were sufficiently accurate compared with retrospective study designs. Further, average follow-up was less than 1 year, at over 11 months. However, the primary outcomes evaluated are early complications that would be expected to occur well before the average follow-up period. Future directions will include refinement of the risk assessment tool and focus on comparison of outcomes in reconstructions assessed with and without this risk assessment tool to determine its broader efficacy in reducing ischemic risk via improved detection.

CONCLUSIONS
===========

In conclusion, ischemic complications after immediate breast reconstruction were positively correlated with higher scores using the sensitive and effective clinical intraoperative mastectomy flap ischemia risk assessment tool established in this study. A threshold value of 6 or greater from a total possible score of 8 indicates significantly greater risk of postoperative mastectomy flap ischemia. This simple, easy-to-implement tool may assist plastic surgeons in assessing risk and optimizing outcomes in immediate postmastectomy breast reconstruction.
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